Skip to main content
Contact Us
Subscribe
E-Edition
50°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Archives
Best of 2025
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Revance Therapeutics, Inc. - Common Stock
(NQ:
RVNC
)
3.650
UNCHANGED
Last Price
Updated: 4:00 PM EST, Feb 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Revance Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
3 Healthcare Stocks to Sell in September Before They Crash & Burn
September 06, 2023
The prognosis for these healthcare stocks isn't optimistic so plan to sell them this month before they get worse.
Via
InvestorPlace
3 Very Oversold Biotech Stocks to Buy Right Now
August 29, 2023
These biotech stocks have tumbled a great deal in recent months, but their long-term outlooks remain quite strong.
Via
InvestorPlace
3 Very Oversold Pharma Stocks to Buy Right Now
August 24, 2023
Oversold pharma stocks have great total return potential. In this article, we list some of the best to buy.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2023
August 16, 2023
Via
Benzinga
Where Revance Therapeutics Stands With Analysts
August 09, 2023
Via
Benzinga
Earnings Preview: Revance Therapeutics
August 07, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Revance Therapeutics
July 11, 2023
Via
Benzinga
How Revance Is Taking A Page Out Of AbbVie's Botox Playbook
August 14, 2023
The company sells a cosmetic treatment. Now, it's bridging into neuroscience.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
July 12, 2023
Via
Benzinga
7 Healthcare Stocks to Make You the Millionaire Next Door
June 21, 2023
For investors who want to greatly increase their wealth in the long term, these are the best healthcare stocks to buy.
Via
InvestorPlace
Analyst Expectations for Revance Therapeutics's Future
June 07, 2023
Via
Benzinga
Earnings Preview For Revance Therapeutics
May 08, 2023
Via
Benzinga
7 Analysts Have This to Say About Revance Therapeutics
April 11, 2023
Via
Benzinga
What 4 Analyst Ratings Have To Say About Revance Therapeutics
January 24, 2023
Via
Benzinga
7 Stocks to Buy for the Massive Rally Ahead
April 04, 2023
With economic growth poised to exceed expectations in 2023, here are seven stocks to buy for a market rally.
Via
InvestorPlace
Earnings Scheduled For February 28, 2023
February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter.
Via
Benzinga
3 Pharma Stocks That Will Mint Millionaires
January 30, 2023
These pharma stocks all have excellent risk-reward ratios and the companies have developed treatments that could easily become blockbusters.
Via
InvestorPlace
Here's Why This Analyst Seems Highly Convinced With Evolus' Outlook
January 19, 2023
Evolus Inc (NASDAQ: EOLS) issued fourth-quarter 2022 and full-year 2022 revenues of $43.6 million, up 26% Y/Y and approximately $148.6 million, up 49%, respectively.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 11, 2023
Via
Benzinga
Tesla, Apple, Nuwellis, Revance, Lululemon: Why These 5 Stocks Are Drawing Investors' Attention Today
January 09, 2023
Major Wall Street indices closed mixed on Monday with the Nasdaq Composite being the only one to end the session on a positive note, led by gains in technology shares. The Dow Jones and the S&P 500...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
January 09, 2023
Via
Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
January 09, 2023
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash.
Via
Benzinga
Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday
January 09, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 150 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Macy's, Acuity Brands And 3 Stocks To Watch Heading Into Monday
January 09, 2023
With US stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
What 8 Analyst Ratings Have To Say About Revance Therapeutics
November 09, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
Revance Therapeutics's Earnings: A Preview
November 07, 2022
Revance Therapeutics (NASDAQ:RVNC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Revance...
Via
Benzinga
What 7 Analyst Ratings Have To Say About Revance Therapeutics
October 11, 2022
Revance Therapeutics (NASDAQ:RVNC) has observed the following analyst ratings within the last quarter:
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October's Key PDUFA Catalysts Biotech Investors Must Know
October 02, 2022
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022
October 11, 2022
Upgrades
Via
Benzinga
'Right Now, You've Still Got To Avoid The Stock,' Jim Cramer Says About This Aerospace Company
September 30, 2022
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Sherwin-Williams Co (NYSE: SHW) might go lower as the PE (price-to-earnings) multiple is still "way too high" on the stock.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.